<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879005</url>
  </required_header>
  <id_info>
    <org_study_id>SRF using DTPA Vs DMSA</org_study_id>
    <nct_id>NCT03879005</nct_id>
  </id_info>
  <brief_title>Split Renal Function Using 99mTc-DTPA Versus 99mTc-DMSA in Kidney Patients of Wide Age Ranges.</brief_title>
  <official_title>Split Renal Function Using 99mTc-DTPA Versus 99mTc-DMSA in Kidney Patients of Wide Age Ranges</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate split renal function using Tc-99m DTPA versus Tc-99m DMSA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Split renal function (SPR) is a determination of the relative contribution of each of the two
      kidneys . It gives a useful information in several conditions such as evaluating unilateral
      renal disorders, assessing individual kidney function before and after intervention, and
      before live donor nephrectomy. Different radiopharmaceuticals such as technetium‐99m
      dimercaptosuccinic acid (99mTc‐DMSA), technetium‐99m diethylenetriaminepentaaceticacid
      (99mTc‐DTPA), technetium‐99m mercaptoacetyltriglycine (99mTc‐MAG3), Iodine 131
      orthoiodohippurate and more recently technetium‐99 m ethylenedicysteine (99mTc‐EC) were used,
      However, 99mTc‑DMSA as a static renal agent is considered the most reliable method to measure
      relative renal function and the most appropriate tracer for renal cortical imaging . In some
      papers, it is emphasized that relative renal function calculated with 99mTc‑DTPA is as
      reliable as 99mTc‑DMSA .‬ The investigators design the study to evaluate the difference in
      estimation of split renal function using the available two radiopharmaceuticals: Tc-99m DTPA
      and Tc-99m DMSA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2019</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Split renal function using 99mTc-DTPA versus 99mTc-DMSA in kidney patients of wide age ranges.</measure>
    <time_frame>one year</time_frame>
    <description>To emphasize that split renal function calculated with Tc-99m DTPA is as reliable as Tc-99m DMSA</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>The Difference in Estimation of Split Renal Function Using the Two Radiopharmaceuticals:Tc-99m DTPA &amp; Tc-99m DMSA in Kidney Patients</condition>
  <arm_group>
    <arm_group_label>Renal scintigraphy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>renal scintigraphy</intervention_name>
    <description>99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.
99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each.</description>
    <arm_group_label>Renal scintigraphy</arm_group_label>
    <other_name>99mTc-DTPA &amp; 99mTc-DMSA renal scintigraphy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Kidney patients of wide age ranges.

          2. Patients with renal disorders who referred for DMSA and DTPA split renal function.

          3. Patients able to sleep in a fixed position for 20 minutes.

        Exclusion Criteria:

          1. Children unable to sit calm without movement during imaging.

          2. Severely ill patients.

          3. Patients with allergy to one or more of material method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed AH Mekkawy, professor</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marwa F Abd El Hay</last_name>
    <phone>0102291658</phone>
    <email>f.marwa1992@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Waleed A Diab, MD</last_name>
    <phone>01004242213</phone>
    <email>Drwaleedin2000@yahoo.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Ardela Díaz E, Miguel Martínez B, Gutiérrez Dueñas JM, Díez Pascual R, García Arcal D, Domínguez Vallejo FJ. [Comparative study of differential renal function by DMSA and MAG-3 in congenital unilateral uropathies]. Cir Pediatr. 2002 Jul;15(3):118-21. Spanish.</citation>
    <PMID>12601986</PMID>
  </results_reference>
  <results_reference>
    <citation>Cao X, Xu X, Grant FD, Treves ST. Estimation of Split Renal Function With (99m)Tc-DMSA SPECT: Comparison Between 3D Volumetric Assessment and 2D Coronal Projection Imaging. AJR Am J Roentgenol. 2016 Dec;207(6):1324-1328. Epub 2016 Sep 13.</citation>
    <PMID>27623376</PMID>
  </results_reference>
  <results_reference>
    <citation>Çelik T, Yalçin H, Günay EC, Özen A, Özer C. Comparison of the Relative Renal Function Calculated with 99mTc-Diethylenetriaminepentaacetic Acid and 99mTc-Dimercaptosuccinic Acid in Children. World J Nucl Med. 2014 Sep;13(3):149-53. doi: 10.4103/1450-1147.144812.</citation>
    <PMID>25538484</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee WG, Kim JH, Kim JM, Shim KM, Kang SS, Chae HI, Choi SH. Renal uptakes of 99mTc-MAG3, 99mTc-DTPA, and 99mTc-DMSA in rabbits with unilateral ureteral obstruction. In Vivo. 2010 Mar-Apr;24(2):137-9.</citation>
    <PMID>20363984</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Marwa Fathy</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Dimercaptosuccinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

